Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus vs Mycophenolate in Expanded Criteria Kidney Transplant
NCT01895049Phase 4Completed
- Start
- Aug 2013
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus in kidney transplant rejection (2 arms). Primary endpoint: Incidence of Cytomegalovirus disease at 1 year. Started Aug 2013; status: completed.
02
Drugs
everolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT01895049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01895049.